Analytical Data
-
基因名
vacA
- Application
-
别名
vacA; HP_0887; Vacuolating cytotoxin autotransporter [Cleaved into: Vacuolating cytotoxin; Vacuolating cytotoxin translocator]
-
种属
Helicobacter pylori
-
表达系统
E. coli
-
标签
N- His-B2M
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P55981
-
表达区间
1018-1290aa
-
分子量
43.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on vacA recombinant protein primarily focuses on its role in understanding and combating Helicobacter pylori, a significant pathogen associated with gastric diseases, including peptic ulcers and gastric cancer. The vacA gene encodes a vacuolating cytotoxin, which is crucial for the bacterium's virulence, facilitating its ability to evade the host immune response and contribute to tissue damage. By studying the recombinant forms of the vacA protein, researchers aim to elucidate the mechanisms through which H. pylori exerts its pathogenic effects and to identify specific immune responses generated by the host. This research holds promise for developing novel diagnostic tools and therapeutic strategies to manage H. pylori infections. Furthermore, the generation of vacA recombinant proteins allows for the exploration of their potential use in vaccine development, enabling the induction of protective immunity in individuals at risk of infection. As global prevalence rates of H. pylori remain high, understanding the molecular and immunological aspects of vacA is essential for addressing the public health challenges posed by related gastrointestinal diseases.
